Abcellera Biologics Inc
NASDAQ: ABCL · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Abcellera Biologics Inc (ABCL) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for ABCL.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
ABCL historical valuation range
Where current P/E sits in ABCL's own 5Y range.
ABCL intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
ABCL valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 23.79x
Is ABCL overvalued in 2026?
Abcellera Biologics Inc (ABCL) currently trades at $5.25 per share with a market capitalization of $1,884,166,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 38/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
ABCL currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 23.8x, the market is valuing the company primarily on its revenue rather than its earnings.
Our discounted cash flow model estimates ABCL's intrinsic value at $8.92 per share, against the current market price of $5.25. This implies a margin of safety of +64.91%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: ABCL appears richly valued on our framework, with a Smart Value Score of 38/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is ABCL overvalued?
ABCL scores 38/100 on our Smart Value Score (Grade D), a weak overall profile. The DCF also shows a positive margin of safety, so price and fundamentals line up reasonably well.
What is ABCL's fair value?
Our DCF model estimates ABCL's intrinsic value at $8.92 per share, versus the current price of $5.25, a margin of safety of +64.91%. Fair value is the present value of the cash flows we project the business to produce, so a price below it means the market is pricing the stock below that conservative estimate.
What P/E ratio does ABCL trade at?
ABCL does not have a meaningful P/E right now, usually a sign of unprofitability or an earnings transition. For unprofitable growth names, price-to-sales is the more useful gauge.
Is ABCL a buy based on valuation?
Our Smart Value rating for ABCL is Sell, from a Smart Value Score of 38/100 that blends growth, quality, and valuation. The profile skews cautious, and a better price or clearer operating improvement would strengthen the case. This is research to inform your decision, not personalized financial advice.
How does ABCL's valuation compare to its history?
There is not enough historical valuation data yet for a confident percentile read on ABCL.
What is ABCL's Smart Value Score?
ABCL's Smart Value Score is 38/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.